Key Developments For Santarus, Inc.
Santarus, Inc. (SNTS.O) (Consolidated Issue listed on NASDAQ Global Market)
Santarus, Inc. Raises FY 2009 Guidance
Santarus, Inc. announced that it has raised fiscal 2009 guidance and now expects total revenues of at least $150 million compared with its prior estimate of $145 million and net income of at least $10 million, compared with prior guidance of breakeven to $1 million. According to Reuters Estimates, analysts are expecting the Company to report revenue of $152 million and net income of $8 million for fiscal 2009.
Santarus, Inc. And Norgine Enter License For ZEGERID Immediate-Release Omeprazole Products In Europe
Santarus, Inc. and Norgine B.V., announced that they have entered into a licensing agreement granting exclusive rights to Norgine to develop, manufacture and commercialize prescription immediate-release ZEGERID products incorporating the proton pump inhibitor omeprazole in combination with one or more buffering agents in specified markets in Western, Central and Eastern Europe. Under the license agreement, Norgine will pay Santarus a $2.5 million upfront fee. Santarus will also be entitled to receive up to an additional $10 million in milestone payments upon the achievement of certain regulatory events, subject to reductions based on Norgine`s actual out-of pocket costs directly related to its clinical, regulatory and reimbursement efforts for a major country as defined under the license agreement. Norgine will also pay Santarus tiered royalties ranging from the mid- to high-teens, subject to reduction in certain limited circumstances, on net sales of any products sold under the license agreement.
Santarus, Inc. Reiterates FY 2009 Revenue Outlook; Raises FY 2009 Net Profit Outlook
Santarus, Inc. reiterated its fiscal 2009 revenue outlook of approximately $145 million. The Company currently expects to achieve a bottom line estimate ranging from breakeven to $1 million in net income for the fiscal 2009, compared with prior outlook of breakeven to a net loss of $3 million.
Santarus, Inc. Reaffirms FY 2009 Guidance
Santarus, Inc. announced that for fiscal 2009, it expects total revenues of approximately $145 million and a bottom line estimate ranging from breakeven to a net loss of $3 million.
Santarus, Inc. Announces FDA Acceptance of New Drug Application for ZEGERID Tablet Product
Santarus, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company`s New Drug Application (NDA) for a new tablet formulation to add to its ZEGERID family of branded prescription pharmaceutical products. Pursuant to Prescription Drug User Fee Act (PDUFA) guidelines, Santarus expects the FDA will complete its review or otherwise respond to the NDA by December 4, 2009.
